Vincent Medical Holdings 過去の業績

過去基準チェック /46

Vincent Medical Holdingsの収益は年間平均-13.6%の割合で減少していますが、 Medical Equipment業界の収益は年間増加しています。収益は年間14.7% 0.5%割合で増加しています。 Vincent Medical Holdingsの自己資本利益率は11.4%であり、純利益率は8.7%です。

主要情報

-13.6%

収益成長率

-13.8%

EPS成長率

Medical Equipment 業界の成長	13.7%
収益成長率	0.5%
株主資本利益率	11.4%
ネット・マージン	8.7%
前回の決算情報	30 Jun 2024

Recent updates

Vincent Medical Holdings Limited's (HKG:1612) Shares Lagging The Market But So Is The Business

Oct 04

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

Aug 23

Investors Met With Slowing Returns on Capital At Vincent Medical Holdings (HKG:1612)

May 21

Returns On Capital Are Showing Encouraging Signs At Vincent Medical Holdings (HKG:1612)

Dec 21

Vincent Medical Holdings (HKG:1612) Is Experiencing Growth In Returns On Capital

Aug 29

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

May 30

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

Dec 15

One Analyst Thinks Vincent Medical Holdings Limited's (HKG:1612) Revenues Are Under Threat

Aug 07

Downgrade: Here's How This Analyst Sees Vincent Medical Holdings Limited (HKG:1612) Performing In The Near Term

Jul 27

Is Vincent Medical Holdings (HKG:1612) A Risky Investment?

Jun 06

One Vincent Medical Holdings Limited (HKG:1612) Analyst Just Slashed Their Estimates By A Material 13%

Mar 28

Vincent Medical Holdings Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Mar 25

Vincent Medical Holdings (HKG:1612) Knows How To Allocate Capital

Mar 23

Have Insiders Been Buying Vincent Medical Holdings Limited (HKG:1612) Shares This Year?

Mar 04

I Ran A Stock Scan For Earnings Growth And Vincent Medical Holdings (HKG:1612) Passed With Ease

Feb 17

Is There An Opportunity With Vincent Medical Holdings Limited's (HKG:1612) 42% Undervaluation?

Feb 04

What You Need To Know About Vincent Medical Holdings Limited's (HKG:1612) Investor Composition

Jan 22

Investors Who Bought Vincent Medical Holdings (HKG:1612) Shares A Year Ago Are Now Up 267%

Jan 08

Has Vincent Medical Holdings Limited's (HKG:1612) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Dec 26

収支内訳

Vincent Medical Holdings の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SEHK:1612 収益、費用、利益 ( )HKD Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	737	64	139	33
31 Mar 24	728	61	139	34
31 Dec 23	718	57	139	36
30 Sep 23	714	55	139	37
30 Jun 23	710	54	139	38
31 Mar 23	669	18	136	37
31 Dec 22	629	-17	134	37
30 Sep 22	658	-21	132	36
30 Jun 22	688	-26	130	35
31 Mar 22	733	18	128	37
31 Dec 21	778	61	125	39
30 Sep 21	901	114	133	40
30 Jun 21	1,024	167	141	41
31 Mar 21	1,090	192	151	39
31 Dec 20	1,155	217	160	37
30 Sep 20	957	153	155	26
30 Jun 20	758	90	150	16
31 Mar 20	630	51	142	8
31 Dec 19	502	12	134	0
30 Sep 19	505	22	130	0
30 Jun 19	507	32	126	0
31 Mar 19	498	31	121	0
31 Dec 18	488	31	117	0
30 Sep 18	478	22	113	0
30 Jun 18	468	14	109	0
31 Mar 18	457	13	108	0
31 Dec 17	446	13	108	0
30 Sep 17	441	21	103	0
30 Jun 17	435	29	98	0
31 Mar 17	451	29	92	0
31 Dec 16	467	29	86	0
30 Sep 16	465	39	81	0
30 Jun 16	462	48	76	0
31 Mar 16	455	53	72	0
31 Dec 15	448	58	68	0
31 Dec 14	389	36	63	0

質の高い収益: 1612は高品質の収益を持っています。

利益率の向上: 1612の現在の純利益率 (8.7%)は、昨年(7.5%)よりも高くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 1612の収益は過去 5 年間で年間13.6%減少しました。

成長の加速: 1612の過去 1 年間の収益成長率 ( 19.4% ) は、5 年間の平均 ( 年間-13.6%を上回っています。

収益対業界: 1612の過去 1 年間の収益成長率 ( 19.4% ) はMedical Equipment業界-9%を上回りました。

株主資本利益率

高いROE: 1612の自己資本利益率 ( 11.4% ) は低いとみなされます。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/03/19 16:44
終値	2025/03/19 00:00
収益	2024/06/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Vincent Medical Holdings Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。1

アナリスト	機関
E Wuen Tan	Crosby Securities Limited

Vincent Medical Holdings 過去の業績

過去 基準チェック /46

主要情報

最近の業績更新

Vincent Medical Holdings Limited to Report Fiscal Year 2024 Results on Mar 19, 2025

First half 2024 earnings released: EPS: HK$0.052 (vs HK$0.041 in 1H 2023)

Vincent Medical Holdings Limited to Report First Half, 2024 Results on Aug 21, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings released: EPS: HK$0.089 (vs HK$0.027 loss in FY 2022)

Vincent Medical Holdings Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

Recent updates

Vincent Medical Holdings Limited to Report Fiscal Year 2024 Results on Mar 19, 2025

New major risk - Revenue and earnings growth

Vincent Medical Holdings Limited's (HKG:1612) Shares Lagging The Market But So Is The Business

First half 2024 earnings released: EPS: HK$0.052 (vs HK$0.041 in 1H 2023)

First half dividend increased to HK$0.016

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

Vincent Medical Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024

Vincent Medical Holdings Limited to Report First Half, 2024 Results on Aug 21, 2024

Upcoming dividend of HK$0.015 per share

Investors Met With Slowing Returns on Capital At Vincent Medical Holdings (HKG:1612)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vincent Medical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.089 (vs HK$0.027 loss in FY 2022)

Vincent Medical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 21 June 2024

Vincent Medical Holdings Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

Vincent Medical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Executive Chairman recently bought HK$239k worth of stock

Returns On Capital Are Showing Encouraging Signs At Vincent Medical Holdings (HKG:1612)

CEO & Executive Director recently bought HK$120k worth of stock

Vincent Medical Holdings (HKG:1612) Is Experiencing Growth In Returns On Capital

Upcoming dividend of HK$0.013 per share at 6.0% yield

First half 2023 earnings released: EPS: HK$0.041 (vs HK$0.068 loss in 1H 2022)

New minor risk - Dividend sustainability

Vincent Medical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 29, 2023

New major risk - Revenue and earnings growth

Vincent Medical Holdings Limited to Report First Half, 2023 Results on Aug 23, 2023

Vincent Medical Holdings Limited Appoints Leung Ming Chu as Non-Executive Director

Executive Chairman recently bought HK$103k worth of stock

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

Vincent Medical Holdings Limited Announces Retirement of Guo Pengcheng as Non-Executive Director

Full year 2022 earnings: EPS exceeds analyst expectations

Vincent Medical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Vincent Medical Holdings Limited Announces FDA 510(K) Clearance of the Inspired Vhb20 Heated Humidifier

Vincent Medical Holdings Limited Announces Board Changes

Is Vincent Medical Holdings (HKG:1612) Using Too Much Debt?

Now 21% undervalued

Less than half of directors are independent

Executive Chairman recently bought HK$417k worth of stock

Upcoming dividend of HK$0.025 per share

Vincent Medical Holdings Limited Announces Special Dividend for the Six Months Ended June 30, 2022, Payable on September 30, 2022

First half 2022 earnings released: HK$0.068 loss per share (vs HK$0.064 profit in 1H 2021)

One Analyst Thinks Vincent Medical Holdings Limited's (HKG:1612) Revenues Are Under Threat

Consensus revenue estimates fall by 18%

Vincent Medical Holdings' (HKG:1612) Returns Have Hit A Wall

Vincent Medical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

VP of Engineering & Executive Director recently bought HK$58k worth of stock

Vincent Medical Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021

Vincent Medical Holdings' (HKG:1612) Dividend Will Be Reduced To HK$0.025

Vincent Medical Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.025 per share

Vincent Medical Holdings' (HKG:1612) Dividend Will Be Reduced To HK$0.025

Price target decreased to HK$1.30

Less than half of directors are independent

Vincent Medical Holdings (HKG:1612) Will Pay A Smaller Dividend Than Last Year

Executive Chairman recently bought HK$211k worth of stock

Consensus revenue estimates fall by 22%

Under The Bonnet, Vincent Medical Holdings' (HKG:1612) Returns Look Impressive

Vincent Medical Holdings Limited to Report Fiscal Year 2021 Results on Mar 23, 2022

Vincent Medical Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2021

Investor sentiment improved over the past week

VP of Engineering & Executive Director recently bought HK$53k worth of stock

Executive Chairman recently bought HK$70k worth of stock

Executive Chairman recently bought HK$240k worth of stock

Executive Chairman recently bought HK$237k worth of stock

Upcoming dividend of HK$0.02 per share

First half 2021 earnings released: EPS HK$0.064 (vs HK$0.14 in 1H 2020)

Investor sentiment deteriorated over the past week

Downgrade: Here's How This Analyst Sees Vincent Medical Holdings Limited (HKG:1612) Performing In The Near Term

Consensus revenue estimates fall to HK$795.0m

過去基準チェック /46